Join the Oncology Voice Network. Join for Free
My Company has been sold, now what?!?”
pharmaceutical acquisitions corporate development biotech innovation market volatility economic downturn strategies

My Company has been sold, now what?!?”


Share This Article


Summary

In this episode, Tom Caravela welcomes Steve St. Onge to discuss the intricacies of corporate acquisitions within the pharmaceutical industry. Steve shares his journey through corporate development and provides insight into the transition and management of acquisitions, both before and after announcements. The conversation delves into the emotional and strategic aspects of navigating acquisitions, identifying warning signs, and the impact of market volatility. Steve offers practical advice for decision-making during economic downturns and strategies for embracing change and new opportunities in the pharma sector. The episode concludes with a discussion on future innovation and optimism in biotech, along with closing remarks and gratitude to listeners.

Steve St. Onge, Sr Director Business Development and Corporate Communications at Paratek discusses what to expect after your company has been acquired.

Steve shares….

👉 What to expect when acquisition news hits
👉 How to handle emotions and not panic
👉 What steps you should take after acquisition news
👉 What are the warning signs to be aware of
👉 Why is the pharma / biotech sector so volatile these days

Click for Source
pharmaceutical acquisitions, corporate development, biotech innovation, market volatility, economic downturn strategies

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Press Release
Visionaries Behind Oncology Voice Network: Dr. Ramin Farhood & Dr. Kirk Shepard
OVN Avatar OVN Staff

Visionaries Behind Oncology Voice Network: Dr. Ramin Farhood & Dr. Kirk Shepard

Article
Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?
OVN Avatar Omer Ben‐Aharon, Racheli Magnezi, Moshe Leshno, and Daniel A. Goldstein

Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?

Press Release
Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes
OVN Avatar OVN Staff

Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes

Press Release
Introducing OncologyVoiceNetwork.com
OVN Avatar OVN Staff

Introducing OncologyVoiceNetwork.com

Article
Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020
OVN Avatar A. Haslam, M.S. Kim, V. Prasad

Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020

Podcast
The Ideal Roadmap for New MSLs
Partner Avatar MSL Talk: Tom Caravela, Sarah Snyder

The Ideal Roadmap for New MSLs

Explore OVN